Abstract:Introduction Ebola virus (EBOV) is an RNA virus of the Filoviridae family that is responsible for outbreaks of hemorrhagic fevers in primates with a lethality rate as high as 90%. EBOV primarily targets host macrophages leading to cell activation and systemic cytokine storm, and fatal infection is associated with an inhibited interferon response, and lymphopenia. The EBOV surface glycoprotein (GP) has been shown to directly induce T cell depletion and can be secreted outside the virion via extracellular vesicles (EVs), though most studies are limited to epithelial cells and underlying mechanisms remain poorly elucidated. Methods To assess the role of GP on EBOV-induced dysregulation of host immunity, we first utilized EBOV virus-like particles (VLPs) expressing VP40 and NP either alone (Bald-VLP) or in conjunction with GP (VLP-GP) to investigate early inflammatory responses in THP-1 macrophages and in a murine model. We then sought to decipher the role of non-classical inflammatory mediators such as EVs over the course of EBOV infection in two EBOV-infected rhesus macaques by isolating and characterizing circulatory EVs throughout disease progression using size exclusion chromatography, nanoparticle tracking-analysis, and LC-MS/MS. Results While all VLPs could induce inflammatory mediators and recruit small peritoneal macrophages, pro-inflammatory cytokine and chemokine gene expression was exacerbated by the presence of GP. Further, quantification of EVs isolated from infected rhesus macaques revealed that the concentration of vesicles peaked in circulation at the terminal stage, at which time EBOV GP could be detected in host-derived exosomes. Moreover, comparative proteomics conducted across EV populations isolated from serum at various time points before and after infection revealed differences in host-derived protein content that were most significantly pronounced at the endpoint of infection, including significant expression of mediators of TLR4 signaling. Discussion These results suggest a dynamic role for EVs in the modification of disease states in the context of EBOV. Overall, our work highlights the importance of viral factors, such as the GP, and host derived EVs in the inflammatory cascade and pathogenesis of EBOV, which can be collectively further exploited for novel antiviral development.

The Lifecycle of the Ebola Virus in Host Cells.

Molecular insights into the Ebola virus life cycle

Resurgence of Ebola Virus: Transmission, Pathogenesis, Prevention and Cure

Molecular mechanisms of Ebola virus pathogenesis: focus on cell death

Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune Evasion

Ebola Virus Disease: Virology, Pathogenesis, Therapy, and Vaccines

A Current Review of Ebola Virus: Pathogenesis, Clinical Presentation, and Diagnostic Assessment

The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development

Interplay Among Constitutes of Ebola Virus: Nucleoprotein, Polymerase L, Viral Proteins

Single-Cell Profiling of Ebola Virus Disease In Vivo Reveals Viral and Host Dynamics

Ebola virus outbreak, updates on current therapeutic strategies

Ebola Virus Entry: From Molecular Characterization to Drug Discovery

Natural history of Ebola virus disease in rhesus monkeys shows viral variant emergence dynamics and tissue-specific host responses

Ebola Virus Disease: General Characteristics, Thoughts, and Perspectives.

Extracellular vesicle storm during the course of Ebola virus infection in primates

Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway

Therapeutic strategies to target the Ebola virus life cycle

Effect of ozone on concentrations of lysozyme in phagocytizing alveolar macrophages.

Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches

Recent Advances in Therapeutic Approaches Against Ebola Virus Infection

Development of Therapeutics for Treatment of Ebola Virus Infection.